|
pubmed:abstractText |
A prophylactic quadrivalent human papillomavirus (HPV) vaccine could benefit adult women if they are susceptible to incident genital HPV infections and are acquiring new infections with vaccine HPV types to which they were previously not exposed. This report presents baseline and prospective data from a randomized, double-blind, placebo-controlled trial of the safety, immunogenicity, and efficacy of the quadrivalent HPV (Type 6/11/16/18) vaccine in women ages 24 to 45.
|
